TEVA PHARMACEUTICAL INDUSTRIES LIMITED Gain (Loss) on Disposition of Business
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) reported Gain (Loss) on Disposition of Business of -$22.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-03.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnSaleOfBusiness · last filed 2026-02-03
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED gain (loss) on disposition of business for the quarter ending 2019-12-31 was $38.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED gain (loss) on disposition of business for the quarter ending 2019-09-30 was $3.00M, a 90.32% decline year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED gain (loss) on disposition of business for the quarter ending 2019-06-30 was $9.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED gain (loss) on disposition of business for the quarter ending 2019-03-31 was -$1.00M, a 101.08% decline year-over-year.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED gain (loss) on disposition of business for fiscal 2025 was -$22.00M, a 246.67% decline from fiscal 2024.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED gain (loss) on disposition of business for fiscal 2024 was $15.00M, a 400.00% increase from fiscal 2023.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED gain (loss) on disposition of business for fiscal 2023 was $3.00M, a 93.48% decline from fiscal 2022.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED gain (loss) on disposition of business for fiscal 2022 was $46.00M, a 9.80% decline from fiscal 2021.
| Period end | Gain (Loss) on Disposition of Business 3 month | Gain (Loss) on Disposition of Business 6 month | Gain (Loss) on Disposition of Business 9 month | Gain (Loss) on Disposition of Business 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$22.00M 10-K · filed 2026-02-03 | |||
| 2024-12-31 | $15.00M 10-K · filed 2026-02-03 | |||
| 2023-12-31 | $3.00M 10-K · filed 2026-02-03 | |||
| 2022-12-31 | $46.00M 10-K · filed 2025-02-05 | |||
| 2021-12-31 | $51.00M 10-K · filed 2024-02-12 | |||
| 2020-12-31 | $8.00M 10-K · filed 2023-02-10 | |||
| 2019-12-31 | $38.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $41.00M derived: sum of 2 quarters · filed 2022-02-09 | $50.00M derived: sum of 3 quarters · filed 2022-02-09 | $50.00M 10-K · filed 2022-02-09 |
| 2019-09-30 | $3.00M 10-Q · filed 2019-11-07 | $12.00M derived: sum of 2 quarters · filed 2019-11-07 | $12.00M 10-Q · filed 2019-11-07 | -$36.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-06-30 | $9.00M 10-Q · filed 2019-08-07 | $9.00M 10-Q · filed 2019-08-07 | -$39.00M derived: sum of 3 quarters · filed 2021-02-10 | -$8.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-03-31 | -$1.00M 10-Q · filed 2019-05-02 | -$48.00M derived: sum of 2 quarters · filed 2021-02-10 | -$17.00M derived: sum of 3 quarters · filed 2021-02-10 | -$27.00M derived: sum of 4 quarters · filed 2021-02-10 |
| 2018-12-31 | -$47.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10 | -$16.00M derived: sum of 2 quarters · filed 2021-02-10 | -$26.00M derived: sum of 3 quarters · filed 2021-02-10 | $67.00M 10-K · filed 2021-02-10 |
| 2018-09-30 | $31.00M 10-Q · filed 2019-11-07 | $21.00M derived: sum of 2 quarters · filed 2019-11-07 | $114.00M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | -$10.00M 10-Q · filed 2019-08-07 | $83.00M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $93.00M 10-Q · filed 2019-05-02 | |||
| 2017-12-31 | $1.08B 10-K · filed 2020-02-21 | |||
| 2016-12-31 | $720.00M 10-K · filed 2019-02-19 |